Search

Your search keyword '"Fisher, P. J."' showing total 13 results
Start Over Author "Fisher, P. J." Journal neurology
13 results on '"Fisher, P. J."'

1. Reader Response: White Matter Hyperintensities Mediate the Association of Nocturnal Blood Pressure With Cognition

Author

Fisher, Mark J, Paganini-Hill, Annlia, Kawas, Claudia H, Corrada, Maria M, and Fletcher, Evan

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Cardiovascular, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Brain Disorders, Dementia, Clinical Research, Aging, Vascular Cognitive Impairment/Dementia, Neurodegenerative, Acquired Cognitive Impairment, Cerebrovascular, Hypertension, Alzheimer's Disease Related Dementias (ADRD), Blood Pressure, Cognition, Humans, Leukoaraiosis, White Matter, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Published
2021

2. Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1

Author

Plotkin, Scott R, Davis, Stephanie D, Robertson, Kent A, Akshintala, Srivandana, Allen, Julian, Fisher, Michael J, Blakeley, Jaishri O, Widemann, Brigitte C, Ferner, Rosalie E, and Marcus, Carole L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Clinical Research, Lung, Neurosciences, Rare Diseases, Neurofibromatosis, Clinical Trials and Supportive Activities, Sleep Research, Respiratory, Clinical Trials as Topic, Humans, Neurofibroma, Plexiform, Neurofibromatosis 1, Oscillometry, Polysomnography, Sleep, Spirometry, Treatment Outcome, REiNS International Collaboration, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectivePlexiform neurofibromas (PNs) are complex, benign nerve sheath tumors that occur in approximately 25%-50% of individuals with neurofibromatosis type 1 (NF1). PNs that cause airway compromise or pulmonary dysfunction are uncommon but clinically important. Because improvement in sleep quality or airway function represents direct clinical benefit, measures of sleep and pulmonary function may be more meaningful than tumor size as endpoints in therapeutic clinical trials targeting airway PN.MethodsThe Response Evaluation in Neurofibromatosis and Schwannomatosis functional outcomes group reviewed currently available endpoints for sleep and pulmonary outcomes and developed consensus recommendations for response evaluation in NF clinical trials.ResultsFor patients with airway PNs, polysomnography, impulse oscillometry, and spirometry should be performed to identify abnormal function that will be targeted by the agent under clinical investigation. The functional group endorsed the use of the apnea hypopnea index (AHI) as the primary sleep endpoint, and pulmonary resistance at 10 Hz (R10) or forced expiratory volume in 1 or 0.75 seconds (FEV1 or FEV0.75) as primary pulmonary endpoints. The group defined minimum changes in AHI, R10, and FEV1 or FEV0.75 for response criteria. Secondary sleep outcomes include desaturation and hypercapnia during sleep and arousal index. Secondary pulmonary outcomes include pulmonary resistance and reactance measurements at 5, 10, and 20 Hz; forced vital capacity; peak expiratory flow; and forced expiratory flows.ConclusionsThese recommended sleep and pulmonary evaluations are intended to provide researchers with a standardized set of clinically meaningful endpoints for response evaluation in trials of NF1-related airway PNs.

Published
2016

3. Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment.

Author

Ahlawat, Shivani, Ly, K. Ina, Fayad, Laura M., Fisher, Michael J., Lessing, Andrés J., Berg, Dale J., Salamon, Johannes M., Mautner, Victor-Felix, Babovic-Vuksanovic, Dusica, Dombi, Eva, Harris, Gordon, Plotkin, Scott R., Blakeley, Jaishri, REiNS International Collaboration, Ahlawat, S, Ina Ly, K, Fayad, L M, Fisher, M J, Lessing, A, and Berg, D

Published
2021
Full Text
View/download PDF

5. Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2.

Author

Akshintala, Srivandana, Khalil, Nashwa, Yohay, Kaleb, Muzikansky, Alona, Allen, Jeffrey, Yaffe, Anna, Gross, Andrea M., Fisher, Michael J., Blakeley, Jaishri O., Oberlander, Beverly, Pudel, Miriam, Engelson, Celia, Obletz, Jaime, Mitchell, Carole, Widemann, Brigitte C., Stevenson, David A., Plotkin, Scott R., and REiNS International Collaboration

Published
2021
Full Text
View/download PDF

9. Recommendations for imaging tumor response in neurofibromatosis clinical trials.

Author

Dombi, Eva, Ardern-Holmes, Simorte L., Babovic-Vuksanovic, Dusica, Barker, Fred G., Connor, Steve, Evans, D. Gareth, Fisher, Michael J., Goutagny, Stephane, Harris, Gordon J., Jaramillo, Diego, Karajannis, Matthias A., Korf, Bruce R., Mautner, Victor, Plotkin, Scott R., Poussaint, Tina Y., Robertson, Kent, Shih, Chie-Schin, and Widemann, Brigitte C.

Published
2013
Full Text
View/download PDF

11. Achieving consensus for clinical trials.

Author

Plotkin, Scott R., Blakeley, Jaishri O., Dombi, Eva, Fisher, Michael J., Hanemann, C. Oliver, Walsh, Karin S., Wolters, Pamela L., and Widemann, Brigitte C.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results